XZP 6019
Alternative Names: XZP-6019Latest Information Update: 07 Oct 2021
Price :
$50 *
At a glance
- Originator XuanZhu Pharma
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 07 Oct 2021 Xuanzhu Biopharmaceutical plans to file IND application for Non-alcoholic steatohepatitis (NASH) in 2021
- 01 Oct 2021 Preclinical trials in Non-alcoholic fatty liver disease in China (PO) before October 2021
- 01 Oct 2021 Preclinical trials in Non-alcoholic steatohepatitis in China (PO) before October 2021